Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 38

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 38
---
) | Pursuant to the Tender Offer, on August 13, 2024, the company cancelled one outstanding option grant then held by Dr. Jalota: an option for 125,000 shares of common stock, initially granted to Dr. Jalota on May 12, 2023. Pursuant to the Tender Offer, in exchange for such cancelled option grant, the company granted one new option grant to Dr. Jalota on August 13, 2024: an option for 125,000 shares of common stock. Such new option grant vests as to 1/4th of the shares of our common stock underlying it on August 13, 2025, and 1/48th vest each month thereafter, subject to the named executive officer’s continued service through each vesting date. |

401(k) Plan We maintain a 401(k) retirement savings plan for the benefit of our employees, including our named executive officers, who satisfy certain eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Internal Revenue Code of 1986, as amended (the “Code”). The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code. We do not provide for any matching contributions under the 401(k) plan. Potential Payments upon Termination or Change in Control Severance Policy . Dr. Mack, Dr. Jalota, and Mr. Carulli are each participants in our Severance Policy. Under their participation agreements, if, within the period three months prior to and 12 months following a “change in control” (such period, the change in control period), we terminate the employment of the applicable named executive officer other than for “cause”, death or “disability” or the applicable named executive officer terminates his or her employment for “good reason” (as such terms are defined in the named executive officer’s change in control and severance agreement) and the named executive officer executes a separation agreement and release of claims that becomes effective and irrevocable within 60 days following the named executive officer’s termination, the named executive officer is entitled to receive (i) a lump sum severance payment, less applicable withholdings, equal to 100%, in the case of Dr. Jalota and Mr. Carulli, and 150%, in the case of Dr. Mack, of their base salary, as then in effect, (ii)